Hey! Are you looking for the mind medicine stock forecast for the upcoming years? This article is currently the best bet for you to get started.
Mind Medicine (MindMeld), Inc. is a neuro-pharmaceutical company that finds, creates, and uses psychedelic medications to enhance wellbeing, lessen suffering, and promote good health. The company creates an ibogaine derivative without the hallucinogenic effects.
What is Mind Medicine Stock?
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company based in Canada. The company is working on products to treat brain health disorders, particularly on psychiatry, addiction, pain, and neurology.
The company is working on a pipeline of drug candidates that target the serotonin, dopamine, and acetylcholine systems. This includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, such as lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA), and zolunicant, as well as 18-methoxycoronaridine (MC), an ibogaine congener. Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMeld GmbH are the company’s subsidiaries.
Is MindMed Stock a Good Buy?
Mind Medicine (MindMed) has a Buy consensus rating. The average rating score for the company is 3.00, based on 3 buy ratings, no hold ratings, and no sell ratings.
The table below shows the stock price prediction for Mind medicine
Mind Medicine Stock Forecast 2023
The table below shows the stock price prediction for Mind medicine
| Date | Price Target | Change |
| 2023 Jan. | $3.43 | -1.53% |
| 2023 Feb. | $3.35 | -1.94% |
| 2023 Mar. | $3.29 | -2.04% |
| 2023 Apr. | $3.22 | -2.22% |
| 2023 May. | $3.13 | -2.56% |
| 2023 Jun. | $3.04 | -3.03% |
| 2023 Jul. | $2.93 | -3.49% |
| 2023 Aug. | $2.83 | -3.58% |
| 2023 Sep. | $2.72 | -3.43% |
| 2023 Oct. | $2.64 | -3.25% |
| 2023 Nov. | $2.53 | -3.23% |
| 2023 Dec. | $2.46 | -3.67% |
Mind Medicine Stock Forecast 2024
The table below shows the stock price prediction for Mind medicine
| Date | Price Target | Change |
| 2024 Jan. | $2.37 | -3.44% |
| 2024 Feb. | $2.31 | -3.41% |
| 2024 Mar. | $2.22 | -3.28% |
| 2024 Apr. | $2.15 | -3.03% |
| 2024 May. | $2.10 | -2.32% |
| 2024 Jun. | $2.07 | -1.56% |
| 2024 Jul. | $2.04 | -0.83% |
| 2024 Aug. | $2.04 | -0.21% |
| 2024 Sep. | $2.03 | 0.38% |
| 2024 Oct. | $2.06 | 0.77% |
| 2024 Nov. | $2.11 | 0.96% |
| 2024 Dec. | $2.13 | 1.04% |
Mind Medicine Stock Forecast 2025
The table below shows the stock price prediction for Mind medicine.
| Date | Price Target | Change |
| 2025 Jan. | $2.15 | 1.03% |
| 2025 Feb. | $2.14 | 0.84% |
| 2025 Mar. | $2.17 | 0.67% |
| 2025 Apr. | $2.18 | 0.50% |
| 2025 May. | $2.21 | 0.41% |
| 2025 Jun. | $2.22 | 0.32% |
| 2025 Jul. | $2.21 | 0.28% |
| 2025 Aug. | $2.20 | 0.24% |
| 2025 Sep. | $2.24 | 0.16% |
| 2025 Oct. | $2.23 | 0.06% |
| 2025 Nov. | $2.26 | -0.02% |
| 2025 Dec. | $2.24 | -0.03% |
Mind Medicine Stock Forecast 2026
The table below shows the stock price prediction for Mind medicine
| Date | Price Target | Change |
| 2026 Jan. | $2.21 | -0.03% |
| 2026 Feb. | $2.23 | 0.05% |
| 2026 Mar. | $2.21 | 0.10% |
| 2026 Apr. | $2.21 | 0.14% |
| 2026 May. | $2.24 | 0.16% |
| 2026 Jun. | $2.25 | 0.09% |
| 2026 Jul. | $2.23 | -0.11% |
| 2026 Aug. | $2.21 | -0.27% |
| 2026 Sep. | $2.20 | -0.61% |
| 2026 Oct. | $2.18 | -0.73% |
| 2026 Nov. | $2.16 | -0.97% |
| 2026 Dec. | $2.14 | -1.07% |
Read Also:
GE Stock Price Forecast For 2023, 2025, and 2027
Didi Stock Price Forecast 2023 – 2025 – 2030
Ford Stock Forecast 2023 -2025 – 2030
Mind Medicine Stock Forecast 2027
The table below shows the stock price prediction for Mind medicine.
| Date | Price Target | Change |
| 2027 Jan. | $2.11 | -1.04% |
| 2027 Feb. | $2.09 | -1.02% |
| 2027 Mar. | $2.07 | -0.94% |
| 2027 Apr. | $2.05 | -0.85% |
| 2027 May. | $2.04 | -0.64% |
| 2027 Jun. | $2.06 | -0.40% |
| 2027 Jul. | $2.03 | -0.21% |
| 2027 Aug. | $2.02 | 0.06% |
| 2027 Sep. | $2.04 | 0.32% |
| 2027 Oct. | $2.06 | 0.52% |
| 2027 Nov. | $2.08 | 0.58% |
| 2027 Dec. | $2.09 | 0.54% |
Mind Medicine Stock Forecast 2028
The table below shows the stock price prediction for Mind medicine.
| Date | Price Target | Change |
| 2028 Jan. | $2.08 | 0.41% |
| 2028 Feb. | $2.07 | 0.22% |
| 2028 Mar. | $2.06 | 0.03% |
| 2028 Apr. | $2.08 | -0.20% |
| 2028 May. | $2.08 | -0.34% |
| 2028 Jun. | $2.06 | -0.50% |
| 2028 Jul. | $2.05 | -0.53% |
| 2028 Aug. | $2.05 | -0.52% |
| 2028 Sep. | $2.03 | -0.45% |
| 2028 Oct. | $2.02 | -0.33% |
| 2028 Nov. | $2.04 | -0.26% |
| 2028 Dec. | $2.03 | -0.22% |
Mind Medicine Stock Forecast 2029
The table below shows the stock price prediction for Mind medicine
| Date | Price Target | Change |
| 2029 Jan. | $2.03 | -0.15% |
| 2029 Feb. | $2.04 | -0.06% |
| 2029 Mar. | $2.01 | 0.05% |
| 2029 Apr. | $2.04 | 0.17% |
| 2029 May. | $2.02 | 0.29% |
| 2029 Jun. | $2.05 | 0.33% |
| 2029 Jul. | $2.06 | 0.34% |
| 2029 Aug. | $2.03 | 0.34% |
| 2029 Sep. | $2.04 | 0.17% |
| 2029 Oct. | $2.06 | -0.02% |
| 2029 Nov. | $2.07 | -0.32% |
| 2029 Dec. | $2.08 | -0.63% |
Mind Medicine Stock Forecast 2030
The table below shows the stock price prediction for Mind medicine
| Date | Price Target | Change |
| 2030 Jan. | $2.03 | -0.85% |
| 2030 Feb. | $2.01 | -0.87% |
| 2030 Mar. | $1.98 | -0.73% |
| 2030 Apr. | $1.97 | -0.47% |
| 2030 May. | $1.96 | -0.23% |
| 2030 Jun. | $1.96 | -0.18% |
| 2030 Jul. | $1.95 | -0.14% |
| 2030 Aug. | $1.94 | -0.08% |
| 2030 Sep. | $1.95 | -0.06% |
| 2030 Oct. | $1.95 | 0.03% |
| 2030 Nov. | $1.94 | 0.11% |
| 2030 Dec. | $1.96 | 0.19% |
FAQS
Why is MindMed stock dropping?
MindMed’s share price has recently fallen due to changes in the broader macroeconomic landscape. The FDA recently approved MindMed’s IND application, causing the company’s stock to rise. Nonetheless, MindMeld has dropped 67% in the last year.
When did MNMD go public?
The MindMed stock began trading on the Nasdaq Capital Market on Tuesday, April 27th, 2021. The MindMed stock is traded on the Nasdaq under the ticker symbol MNMD.
Who invested in Mnmd?
Top 10 Owners of Mind Medicine (MindMed) Inc
| · Stockholder | Stake | Shares owned | Total value ($) |
| · Millennium Management LLC | 1.20% | 5,075,110 | 3,527,201 |
| · Citadel Advisors LLC | 0.41% | 1,741,833 | 1,210,574 |
| · Busey Bank (Investment Management… | 0.30% | 1,248,201 | 867,500 |
| · SSgA Funds Management, Inc. | 0.23% | 962,810 | 669,153 |
| · Schweizerische Nationalbank (Inve… | 0.20% | 848,400 | 589,638 |
| · LPL Financial LLC | 0.18% | 774,711 | 538,424 |
| · AdvisorShares Investments LLC | 0.18% | 750,151 | 521,355 |
| · Susquehanna Financial Group LLLP | 0.15% | 632,746 | 439,758 |
| · Group One Trading LP | 0.13% | 566,863 | 393,970 |
| · Merit Financial Group LLC | 0.13% | 532,387 | 370,009 |
Will MindMed go up?
Wall Street is optimistic about Mind Medicine (MindMed) Inc. (MNMD). MNMD is rated a Strong Buy by analysts on average. The average price target is $8, implying that analysts expect the stock to rise by 633.94% over the next year.
What is Mind Medicine (MindMed)’s stock symbol?
Mind Medicine (MindMed) is a company that trades on the NASDAQ under the symbol “MNMD.”
Who is Mind Medicine (MindMed)’s, major shareholders?
Many institutional and retail investors own Mind Medicine (MindMed) stock. Millennium Management LLC (1.20%), State Street Corp (0.23%), Swiss National Bank (0.20%), LPL Financial LLC (0.18%), AdvisorShares Investments LLC (0.18%), and Merit Financial Group LLC (0.13%) are the top institutional investors. Insiders who own company stock include Dan Karlin and Robert Barrow.
Conclusion
Mind Medicine stocks are expected to experience strong growth in the coming years. This is due to the increasing awareness of the potential benefits of mind-based therapies and the growing demand for these treatments.
About Author
-
My name is Precious Ejiofor, I am a professional self motivated, dependable writer and editor, with over 4 year of experience in writing for variety of business and platforms. I am able and capable to write on any kind of topic.
Specifically, I focus on producing persuasive and compelling contents that is thoughtful, prominent, and engaging.
